TARGET AUDIENCE
This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of Hodgkin lymphoma (HL), non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL).

OVERVIEW OF ACTIVITY
The unique clinical characteristics and treatment considerations of the many individual cancers originating from the blood, lymph or marrow necessitate the subdivision of these diseases by common etiologic pathway. These categories include the lymphomas, the leukemias, multiple myeloma and related disorders (eg, myelodysplastic syndromes, myeloproliferative diseases) stemming from lymphoid and myeloid progenitor cell lines. The need for continuing education on all hematologic cancer subtypes is great, particularly for HL and NHL, including CLL. The current list of available treatment options is extensive, which, while reassuring for patients and oncology healthcare professionals, poses quite a challenge to the practicing clinician who must maintain up-to-date knowledge of appropriate clinical management strategies across a vast spectrum of liquid and solid tumors. Over the past several years, substantial progress has been made in the development and evaluation of novel agents for various lymphoma subtypes. Mature clinical trial results have illustrated the efficacy of several new investigational therapies, a number of which have now entered the clinic, altering the therapeutic algorithms for HL and various subtypes of NHL. Furthermore, as novel agents and strategies have been associated with impressive clinical benefit, there is widespread enthusiasm that additional important advances are on the near horizon.

Although medical oncologists have been routinely responsible for counseling patients with regard to therapeutic decision-making, oncology nurses play an integral role in the successful delivery of systemic anticancer therapy and the preservation of patient physical and psychosocial well-being. These video proceedings from the fourth part of a 7-part integrated CNE curriculum originally held at the 2017 ONS Annual Congress feature discussions with leading lymphoma investigators and their nursing counterparts regarding actual patient cases and recent clinical research findings affecting the optimal therapeutic and supportive care for each patient scenario.

LEARNING OBJECTIVES
• Provide patient-focused education to enhance clinical decision-making regarding the available systemic agents used in the management of indolent and aggressive forms of B-cell and T-cell lymphomas and HL.
• Appreciate the contribution of patient performance status/comorbidities, biomarker profile, prior therapeutic exposure and psychosocial status on the selection and sequence of systemic therapy for newly diagnosed and relapsed/refractory (R/R) CLL.
• Review recent therapeutic advances in the management of newly diagnosed and R/R diffuse large B-cell, follicular and mantle cell lymphoma, and use this information to counsel patients regarding protocol and nonresearch options.
• Consider available and emerging data informing the clinical use of brentuximab vedotin and immune checkpoint inhibitors in the therapeutic management of HL.

ACCREDITATION STATEMENT
Research To Practice is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

CREDIT DESIGNATION STATEMENT
This educational activity for 2.2 contact hours is provided by Research To Practice during the period of July 2017 through July 2018.

This activity is awarded 2.2 ANCC pharmacotherapeutic contact hours.

ONCC/ILNA CERTIFICATION INFORMATION
The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points. To review certification qualifications please visit ResearchToPractice.com/ONS2017/ILNA.

ONCC review is only for designating content to be used for recertification points and is not for CNE accreditation. CNE programs must be formally approved for contact hours by an
acceptable accreditor/approver of nursing CE to be used for recertification by ONCC. If the CNE provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification may be used in relation to the program.

FOR SUCCESSFUL COMPLETION
This is a video CNE program. To receive credit, participants should read the learning objectives and faculty disclosures, watch the video, complete the Post-test with a score of 80% or better and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/ONSLymphomas2017/CNE.

CONTENT VALIDATION AND DISCLOSURES
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CNE activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

Ann S LaCasce, MD, MMSc
Program Director, Fellowship in Hematology/Oncology Associate Professor of Medicine, Harvard Medical School Lymphoma Program
Dana-Farber Cancer Institute
Boston, Massachusetts

Advisory Committee: Forty Seven Inc.

Kim Leake, MSN, FNP-C, APN-1
Division of Hematology and Oncology University of Virginia Health System
Charlottesville, Virginia

No relevant conflicts of interest to disclose.

Mollie Moran, MSN, CNP, AOCNP
The James Cancer Hospital at The Ohio State University
Columbus, Ohio

No relevant conflicts of interest to disclose.

Michael E Williams, MD, ScM
Byrd S Leavell Professor of Medicine
Chief, Hematology/Oncology Division University of Virginia School of Medicine
Charlottesville, Virginia

Advisory Committee and Consulting Agreements: Celgene Corporation, Gilead Sciences Inc, Takeda Oncology, TG Therapeutics Inc; Contracted Research: Allos Therapeutics, Celgene Corporation, Gilead Sciences Inc, Novartis, TG Therapeutics Inc.


RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no relevant conflicts of interest to disclose.

This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

This activity is supported by educational grants from AbbVie Inc, AstraZeneca Pharmaceuticals LP/Acerta Pharma, Celgene Corporation, Genentech BioOncology, Janssen Biotech Inc, Pharmacyclics LLC, an AbbVie Company and Seattle Genetics.

Hardware/Software Requirements:
A high-speed Internet connection
A monitor set to 1280 x 1024 pixels or more
Internet Explorer 7 or later, Firefox 3.0 or later, Chrome, Safari 3.0 or later
Adobe Flash Player 10.2 plug-in or later
Adobe Acrobat Reader
(Optional) Sound card and speakers for audio

Last review date: July 2017
Expiration date: July 2018

There is no implied or real endorsement of any product by RTP or the American Nurses Credentialing Center.


Chen RW et al. Results of a phase II trial of brentuximab vedotin as first line salvage therapy in relapsed/refractory HL prior to AHCT. *Proc ASH* 2014;Abstract 501.


Woyach JA et al. The B-cell receptor signaling pathway as a therapeutic target in CLL. Blood 2012;120(6):1175-84.